Eupraxia Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRX research report →
Companywww.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc. , a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
- CEO
- James A. Helliwell
- IPO
- 2024
- Employees
- 33
- HQ
- Victoria, BC, CA
Price Chart
Valuation
- Market Cap
- $213.27M
- P/E
- -7.68
- P/S
- 0.00
- P/B
- 2.61
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.05%
- ROIC
- -36.05%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-53,858,075 · -5.18%
- EPS
- $-1.05 · -38.16%
- Op Income
- $-53,659,677
- FCF YoY
- 1.57%
Performance & Tape
- 52W High
- $9.32
- 52W Low
- $3.67
- 50D MA
- $7.23
- 200D MA
- $6.77
- Beta
- 2.82
- Avg Volume
- 199.09K
Get TickerSpark's AI analysis on EPRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EPRX Coverage
We haven't published any research on EPRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EPRX Report →